Eurocine Vaccines Past Earnings Performance
Past criteria checks 0/6
Eurocine Vaccines has been growing earnings at an average annual rate of 3.4%, while the Biotechs industry saw earnings declining at 1.4% annually. Revenues have been growing at an average rate of 2.7% per year.
Key information
3.4%
Earnings growth rate
80.2%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | 2.7% |
| Return on equity | n/a |
| Net Margin | -215,114.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Eurocine Vaccines makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -15 | 15 | 0 |
| 30 Sep 23 | 0 | -14 | 14 | 0 |
| 30 Jun 23 | 0 | -18 | 18 | 0 |
| 31 Mar 23 | 0 | -20 | 20 | 0 |
| 31 Dec 22 | 0 | -23 | 23 | 0 |
| 30 Sep 22 | 0 | -22 | 22 | 0 |
| 30 Jun 22 | 0 | -20 | 20 | 0 |
| 31 Mar 22 | 0 | -21 | 30 | 0 |
| 31 Dec 21 | 0 | -20 | 20 | 0 |
| 30 Sep 21 | 0 | -19 | 19 | 0 |
| 30 Jun 21 | 0 | -18 | 19 | 0 |
| 31 Mar 21 | 0 | -15 | 10 | 0 |
| 31 Dec 20 | 0 | -12 | 12 | 0 |
| 30 Sep 20 | 0 | -11 | 10 | 0 |
| 30 Jun 20 | 0 | -9 | 9 | 0 |
| 31 Mar 20 | 0 | -10 | 7 | 0 |
| 31 Dec 19 | 0 | -11 | 11 | 0 |
| 30 Sep 19 | 0 | -18 | 18 | 0 |
| 30 Jun 19 | 0 | -21 | 21 | 0 |
| 31 Mar 19 | 0 | -26 | 26 | 0 |
| 31 Dec 18 | 0 | -39 | 39 | 0 |
| 30 Sep 18 | 0 | -40 | 40 | 0 |
| 30 Jun 18 | 0 | -42 | 42 | 0 |
| 31 Mar 18 | 0 | -40 | 40 | 0 |
| 31 Dec 17 | 0 | -30 | 30 | 0 |
| 30 Sep 17 | 0 | -27 | 7 | 0 |
| 30 Jun 17 | 0 | -26 | 26 | 0 |
| 31 Mar 17 | 0 | -26 | 15 | 0 |
| 31 Dec 16 | 0 | -24 | 12 | 0 |
| 30 Sep 16 | 0 | -18 | 7 | 0 |
| 30 Jun 16 | 0 | -16 | 16 | 0 |
| 31 Mar 16 | 0 | -13 | 11 | 0 |
| 31 Dec 15 | 0 | -12 | 10 | 0 |
| 30 Sep 15 | 1 | -11 | 6 | 0 |
| 30 Jun 15 | 1 | -10 | 5 | 0 |
| 31 Mar 15 | 1 | -10 | 5 | 0 |
| 31 Dec 14 | 1 | -10 | 5 | 0 |
| 30 Sep 14 | 1 | -11 | 5 | 0 |
| 30 Jun 14 | 1 | -11 | 4 | 0 |
| 31 Mar 14 | 0 | -11 | -3 | 0 |
| 31 Dec 13 | 0 | -12 | 0 | 0 |
| 30 Sep 13 | 0 | -13 | 5 | 0 |
Quality Earnings: EUCI is currently unprofitable.
Growing Profit Margin: EUCI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EUCI is unprofitable, but has reduced losses over the past 5 years at a rate of 3.4% per year.
Accelerating Growth: Unable to compare EUCI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EUCI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14.4%).
Return on Equity
High ROE: EUCI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.